Lung staging: N2 or N3?
A man in his seventies with severe chronic obstructive pulmonary disease (COPD) has a 1.7 cm squamous cell carcinoma in the left lower lobe. On endobronchial ultrasound, the right hilar node (11R) is positive; stations 7 and 4L are negative. The tumor is small. What stage is it?
Concepts first
- TNM
- tumor, nodes, metastasis
- Station
- a numbered place on the node map of the IASLC (International Association for the Study of Lung Cancer)
- Side
- same side or other side, judged against the tumor
- EBUS
- endobronchial ultrasound: a needle through the airway into the node
- c and p
- clinical stage comes from imaging and biopsies; pathological from the resected specimen
- 9th edition
- AJCC Version 9 for lung in the US, for cancers diagnosed from January 1, 2025
A node in front of the trachea is 4R.The midline is the left edge of the trachea, not its middle: right paratracheal 2R and 4R reach it, so that node is N3 for a left tumor. Survival bars: clinical N, 45,032 patients in the 9th edition database (Huang 2024). Most had surgery, so read them as the order of risk, not a number to quote to an unselected patient.
Back to the left lower lobe
Our patient: T1b (over 1 to 2 cm), N3, M0. Clinical stage IIIB, in the 8th and the 9th edition alike.He is not stage I because the tumor is small, and not stage IV either: an opposite hilar node is still regional. That keeps a curative plan on the table, which is the next tab.
Why EBUS samples N3 first.The bronchoscopist goes from N3 to N2 to N1, with a fresh or rinsed needle between stations, so a needle never carries cells from a lower station into one that would raise the stage. The first positive station in that order defines the highest N.
What the 9th edition changed
Why split N2?One N2 station did better than several, in clinical and pathological staging, across histology, T category and region (Huang 2024). Stations, not nodes, because a CT cannot count nodes and a pathologist often cannot either. The subcarinal station 7 counts as one station. The T categories did not change (Van Schil 2024).
Stage groups
Try it: stage calculator
Starts on our patient. Change any box; ticking stations builds N for you.
Positive stations (optional)
Non-small cell and small cell lung cancer, IASLC 9th edition (AJCC Version 9). Stations 3a, 3p, 8 and 9 are left out for simplicity: on the tumor side they count as N2, and each counts as a station.
Memory hooks
Tap a card to flip it.
Check yourself
Question 1Right upper lobe adenocarcinoma, 2.5 cm. EBUS: 4R positive; 7, 4L and 10R negative. No metastasis. Stage?
T1c N2a M0, stage IIB in the 9th edition. Tempting: IIIA, which it was in the 8th. This is one of the moves.
Question 2Same patient, but 4R and 7 are both positive, with 4 positive nodes inside 4R.
Two stations: N2b. T1c N2b is IIIA, unchanged from the 8th. Tempting: counting 5 nodes. Count stations, not nodes.
Question 3Left upper lobe tumor, 3.2 cm. Stations 5 and 6 positive; 4L and 7 negative. Stage?
Two stations, so N2b: T2a N2b M0 is IIIB, the one move up (IIIA in the 8th). Double trap: 5 and 6 sit side by side and look like one group, and T2 N2 used to be IIIA.
Question 4Left upper lobe tumor, 4.5 cm, a second nodule of the same histology in the left lower lobe, nodes negative. Stage? And if the nodule were in the right lung, or there were a malignant pleural effusion instead?
Other lobe, same lung: T4 N0 M0, stage IIIA; the nodule beats the size (T2b). Other lung: M1a, IVA. Malignant effusion: also M1a, IVA, not T4.
Question 5Right lower lobe tumor, 3.5 cm, N0, one adrenal metastasis. Then: three brain metastases and nothing else. Then: brain plus liver.
Adrenal: T2a N0 M1b, IVA. Three in the brain: M1c1, IVB; tempting to call it M1b because it is one organ, but M1b means one lesion. Brain plus liver: M1c2, still IVB.
Question 6Left upper lobe tumor, 2.4 cm. EBUS: a node in front of the lower trachea is positive; 4L and 7 negative. Stage? And if the only positive node were in the right supraclavicular fossa?
A node in front of the trachea is 4R, because right paratracheal reaches the left edge of the trachea: N3 for a left tumor, T1c N3 M0, IIIB. Tempting: "midline, so same side", N2a, IIB. Right supraclavicular: also N3 (station 1, either side), still IIIB; regional, not M1b.
Sources
Retrieved from PubMed, read on Oct 28, 2026.
- Rami-Porta R, Nishimura KK, et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer. J Thorac Oncol 2024;19:1007-1027. doi:10.1016/j.jtho.2024.02.011
- Huang J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol 2024;19:766-785. doi:10.1016/j.jtho.2023.10.012
- Fong KM, Rosenthal A, et al. The IASLC Staging Project for Lung Cancer: proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol 2024;19:786-802. doi:10.1016/j.jtho.2024.01.019
- Van Schil PE, et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T-descriptors in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol 2024;19:749-765. doi:10.1016/j.jtho.2023.12.006
- Tsao MS, et al. The IASLC Staging Project: the database and proposal for the revision of the staging of pulmonary neuroendocrine carcinoma in the forthcoming ninth edition of the TNM classification for lung cancer. J Thorac Oncol 2025;20:856-870. doi:10.1016/j.jtho.2025.01.013
Stage III, frail patient: who gets what
The same man: stage IIIB, not a surgical candidate. Severe COPD, DLCO about half of predicted, heart failure with a mildly reduced ejection fraction, a device in the chest, ECOG 2 on a good day. Concurrent chemoradiation is not realistic. Is he still treated for cure?
Concepts first
- Concurrent
- chemotherapy and radiation in the same weeks
- Sequential
- chemotherapy first, radiation after
- Consolidation
- drug therapy after radiation ends, to keep the cancer down
- ECOG
- performance status, 0 fully active to 4 bedbound; 2 means up and about more than half the day but unable to work
- PD-L1 TPS
- programmed death ligand 1, tumor proportion score: the percentage of tumor cells that stain
- NGS
- next-generation sequencing for driver mutations such as EGFR
- DLCO
- diffusing capacity of the lung for carbon monoxide: how well gas crosses into the blood
- PFS, OS
- progression-free survival (alive without growth); overall survival
Durvalumab after concurrent chemoradiation is the standard.PACIFIC randomized 713 patients with ECOG 0 to 1, 2 to 1, to durvalumab or placebo for 1 year. At 5 years, 42.9% versus 33.4% were alive and 33.1% versus 19.0% alive without progression (overall survival hazard ratio 0.72; Spigel 2022). The US label requires prior concurrent chemoradiation and no progression; PD-L1 is not required.
Back to our patient
Our patient: NGS and PD-L1 are pending.EGFR driver: osimertinib after radiation. No driver and weekly chemotherapy tolerable: low-dose chemotherapy, then radiation, then durvalumab; if PD-L1 is 50% or more, pembrolizumab first is the other option. No chemotherapy possible: radiation, then durvalumab. Every branch is treated for cure.
Low-dose chemotherapy in practice.Weekly carboplatin AUC 2 with paclitaxel 45 mg/m² is the dose RTOG 0617 gave during radiation (Bradley 2015), in patients with ECOG 0 to 1. Given before radiation to a frail patient, it is an extrapolation: PACIFIC-6 used at least 2 full cycles of a platinum doublet. AUC: area under the curve, the carboplatin dose target.
Lung function and the device shape the radiation plan, not the stage.Severe COPD and a low DLCO raise the risk of radiation pneumonitis; the radiation oncologist weighs lung dose against tumor coverage. A pacemaker or defibrillator near the field needs a dose check by the radiation team and a device check with cardiology. Talk before the plan is final, not after.
One more trap.Every trial on this tab staged patients by an older TNM edition. A 9th edition IIB (T1 N2a) was stage III in those trials.
What the gentler paths showed
Sequential, then durvalumab: PACIFIC-6
117 patients, two thirds aged 65 or older. ECOG 2 was allowed, but only 3 patients (2.6%) had it. Median PFS 13.1 months, median OS 39.0 months, 56.5% alive at 3 years. Pneumonitis grade 3 or 4 in 1.7%, 1 death from pneumonitis, and 10% stopped durvalumab for it (Garassino 2025). Single arm, and outside the US label, which names concurrent chemoradiation.
Radiation alone, then durvalumab: DUART
102 patients unfit for any chemotherapy, median age 79, 8% ECOG 2, 39% with COPD; about half got palliative-dose radiation. Median PFS 9.2 months (10.3 after definitive-dose radiation), median OS 21.1 months; grade 3 or 4 related events 9.8% in the first 6 months (Filippi 2025). Also single arm and off label.
Immunotherapy first, no chemo: SPRINT
PD-L1 50% or more, ECOG 0 to 1, 25 patients: pembrolizumab for 3 doses, then radiation in 20 fractions (55 Gy, gray, the radiation dose unit, to larger tumors or nodes, 48 Gy to smaller ones), then pembrolizumab to complete a year. PFS 76% at 1 year; OS 92% at 1 year and 76% at 2 years (Ohri 2024). Small, single arm, fitter patients than ours.
EGFR exon 19 deletion or L858R: osimertinib, not durvalumab
LAURA: 216 patients after chemoradiation, osimertinib versus placebo until progression. Median PFS 39.1 versus 5.6 months, hazard ratio 0.16 (Lu 2024). This is why NGS goes out even on a squamous biopsy: a driver changes the drug that follows radiation.
Memory hooks
Tap a card to flip it.
Check yourself
Question 1Fit 64-year-old, stage IIIA squamous, PD-L1 TPS 5%, no driver, finished concurrent chemoradiation. Consolidation? And if restaging showed a new, proven liver metastasis?
No progression: durvalumab for 1 year; the US label does not require PD-L1. Tempting to hold it because 5% sounds negative, but the 50% cutoff belongs to immunotherapy given alone. A liver metastasis is progression: PACIFIC and the label require none, so he is now treated as stage IV.
Question 2Stage IIIB adenocarcinoma, no progression after chemoradiation. NGS returns EGFR L858R. Durvalumab? And if he already had 2 doses of durvalumab when the result came back?
Osimertinib until progression, not durvalumab (LAURA, PFS 39.1 versus 5.6 months). If durvalumab was already given, osimertinib is still the drug with the benefit, but watch closely: after a PD-1 or PD-L1 inhibitor, 15% had a severe immune adverse event on osimertinib, 24% when it started within 3 months (Schoenfeld 2019, retrospective). The real fix is upstream: NGS back before radiation ends.
Question 3ECOG 2, cannot tolerate concurrent treatment, tolerated 2 cycles of carboplatin, then radiation. No progression. What data support durvalumab now, and what is the catch?
PACIFIC-6: median PFS 13.1 and OS 39.0 months, few severe pneumonitis cases, but 10% stopped durvalumab for pneumonitis. The catch: single arm, only 3 patients with ECOG 2, and the US label names concurrent chemoradiation, so this is off label. Tempting to read PACIFIC-6 as the ECOG 2 trial; it was not.
Question 4ECOG 2, severe COPD, no chemotherapy possible. PD-L1 TPS 70%, no driver. What are the two paths with data?
Radiation, then durvalumab (DUART, median PFS 9.2 months, single arm, off label). Or pembrolizumab first, then radiation if he holds up (SPRINT design, which enrolled ECOG 0 to 1), within the pembrolizumab label for stage III unfit for chemoradiation with TPS 1% or more. Tempting to stop at "no chemo, so DUART" and never ask PD-L1. No trial compares the two.
Question 5Fit patient, cT1c N2a M0 squamous, unresectable because of lung function. The chart says stage IIB. No progression after concurrent chemoradiation, TPS 20%, no driver. Durvalumab?
Yes. In the 7th and 8th editions, which the trials used, T1 N2 was stage IIIA: the anatomy defined who was studied, not the edition label. Tempting: "stage II, so no consolidation". Write both in the note (9th edition IIB, 8th edition IIIA).
Sources
Retrieved from PubMed and FDA labels, read on Oct 28, 2026.
- Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol 2022;40:1301-1311. doi:10.1200/JCO.21.01308
- Garassino MC, Mazieres J, Reck M, et al. Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial. J Thorac Oncol 2022;17:1415-1427. doi:10.1016/j.jtho.2022.07.1148
- Garassino MC, Khalifa J, Reck M, et al. Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer: final analysis from the phase II PACIFIC-6 trial. ESMO Open 2025;10:105071. doi:10.1016/j.esmoop.2025.105071
- Filippi AR, García Campelo MR, Paoli JB, et al. Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study. ESMO Open 2025;10:105560. doi:10.1016/j.esmoop.2025.105560
- Ohri N, Jolly S, Cooper BT, et al. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT). J Clin Oncol 2024;42:562-570. doi:10.1200/JCO.23.00627
- Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol 2019;30:839-844. doi:10.1093/annonc/mdz077
- Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med 2024;391:585-597. doi:10.1056/NEJMoa2402614
- Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819-1830. doi:10.1016/S0140-6736(18)32409-7
- Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-199. doi:10.1016/S1470-2045(14)71207-0
- Remon J, Levy A, Gille R, et al. Unresectable stage III non-small-cell lung cancer: state of the art and challenges. Nat Rev Clin Oncol 2026;23:22-39. doi:10.1038/s41571-025-01080-4
- US prescribing information: Imfinzi (durvalumab), Keytruda (pembrolizumab), Libtayo (cemiplimab). Drugs@FDA